-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $5

Benzinga·05/02/2025 16:56:30
Listen to the news
Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Neutral and lowers the price target from $10 to $5.